Breaking Finance News

BREAKING- Acura Pharma Halted- News Pending (ACUR)

Update: Results from a Phase II study testing were not statistically significant. Read the full release here.

Shares of Acura Pharmaceuticals (NASDAQ: ACUR) are halted with news pending. The stock finished the day nearly 4 percent higher. There was no news to attribute to the company during the trading day.

Acura Pharmaceuticals is a $87 million company that trades an average of 398,000 shares. At the end of the day Monday, the stock had traded only 172,000.

Company Profile:

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. Its products include Oxecta Tablets CII, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, an over-the-counter immediate-release pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. The company has seven additional opioid products utilizing Aversion technology in various stages of development.

Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc., a wholly-owned subsidiary of Pfizer Inc. to develop and commercialize certain opioid analgesic products utilizing the company’s proprietary Aversion technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.